Studying Cell Immune Responses to a Live Flu Vaccine in Healthy Adults
Public ClinicalTrials.gov record NCT01730144. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Elucidation of the Mucosal Immune Responses to Live Attenuated Influenza Vaccine In Healthy Adults
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Background: \- One form of the influenza vaccine is a nasal spray. It uses a live but weakened flu virus. Researchers want to better under how the live vaccine interacts with the body s immune system. They will test the nasal spray flu vaccine (called FluMist) against a saline (salt water) nasal spray. They will then look at blood and nasal cell samples to see how the vaccine affects these cells immune response. Objectives: \- To look at immune changes in nasal and blood cells in people who receive live flu vaccine. Eligibility: \- Healthy volunteers between 18 and 49 years of age. Design: * Participants will have five outpatient visits for this study. Each visit will last up to 2 hours. * At the first visit, participants will have a physical exam and medical history. They will give blood and urine samples. Nasal cell samples will also be collected. * A week later, participants will have either the nasal spray flu vaccine or a saline spray. They will know which spray they will receive. Blood samples will be collected. * Two days after the vaccination, they will have another physical exam. Blood and nasal cell samples will be collected. * At the final two visits (1 week and 1 month after the vaccination), more blood samples will be collected. * Those who had the saline spray will be able to have the actual vaccine spray at the last study visit. * The ratio of participants who receive vaccine to those who receive saline will be 4:1.
Study identification
- NCT ID
- NCT01730144
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 10 participants
Conditions and interventions
Conditions
Interventions
Not listed
Eligibility (public fields only)
- Age range
- 18 Years to 49 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 16, 2012
- Primary completion
- Apr 16, 2013
- Completion
- Jul 11, 2019
- Last update posted
- Oct 17, 2019
2012 – 2019
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda | Maryland | 20892 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01730144, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 17, 2019 · Synced Sep 13, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01730144 live on ClinicalTrials.gov.